132 related articles for article (PubMed ID: 34312777)
41. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
[TBL] [Abstract][Full Text] [Related]
42. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract][Full Text] [Related]
43. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
Hettipathirana T; Macdonald C; Xie J; Moodie K; Michael C; Phillips KA
Med J Aust; 2021 Nov; 215(10):460-464. PubMed ID: 34420218
[TBL] [Abstract][Full Text] [Related]
44. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.
Evans DG; Harkness EF; Howell A; Wilson M; Hurley E; Holmen MM; Tharmaratnam KU; Hagen AI; Lim Y; Maxwell AJ; Moller P
Hered Cancer Clin Pract; 2016; 14():8. PubMed ID: 27087880
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
46. Online tool to guide decisions for BRCA1/2 mutation carriers.
Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
[TBL] [Abstract][Full Text] [Related]
47. Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study.
Nederend J; Duijm LE; Voogd AC; Groenewoud JH; Jansen FH; Louwman MW
Breast Cancer Res; 2012 Jan; 14(1):R10. PubMed ID: 22230363
[TBL] [Abstract][Full Text] [Related]
48. Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.
Chiarelli AM; Blackmore KM; Muradali D; Done SJ; Majpruz V; Weerasinghe A; Mirea L; Eisen A; Rabeneck L; Warner E
J Natl Cancer Inst; 2020 Feb; 112(2):136-144. PubMed ID: 31233143
[TBL] [Abstract][Full Text] [Related]
49. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
50. MRI in the early detection of breast cancer in women with high genetic risk.
Trecate G; Vergnaghi D; Manoukian S; Bergonzi S; Scaperrotta G; Marchesini M; Ferranti C; Peissel B; Spatti G; Bohm S; Conti A; Costa C; Sporeni M; Podo F; Musumeci R
Tumori; 2006; 92(6):517-23. PubMed ID: 17260493
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group.
Møller P; Reis MM; Evans G; Vasen H; Haites N; Anderson E; Steel CM; Apold J; Lalloo F; Maehle L; Preece P; Gregory H; Heimdal K
Dis Markers; 1999 Oct; 15(1-3):179-86. PubMed ID: 10595275
[TBL] [Abstract][Full Text] [Related]
52. Screening of women at high risk for breast cancer.
Narod SA
Prev Med; 2011 Sep; 53(3):127-30. PubMed ID: 21745498
[TBL] [Abstract][Full Text] [Related]
53. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.
Schousboe JT; Kerlikowske K; Loh A; Cummings SR
Ann Intern Med; 2011 Jul; 155(1):10-20. PubMed ID: 21727289
[TBL] [Abstract][Full Text] [Related]
54. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
55. Five-year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer.
Kam JK; Naidu P; Rose AK; Mann GB
J Med Imaging Radiat Oncol; 2013 Aug; 57(4):400-6. PubMed ID: 23870334
[TBL] [Abstract][Full Text] [Related]
56. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
[TBL] [Abstract][Full Text] [Related]
58. Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
Lammert J; Skandarajah AR; Shackleton K; Calder P; Thomas S; Lindeman GJ; Mann GB
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e27-e37. PubMed ID: 31657879
[TBL] [Abstract][Full Text] [Related]
59. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.
Warner E; Plewes DB; Shumak RS; Catzavelos GC; Di Prospero LS; Yaffe MJ; Goel V; Ramsay E; Chart PL; Cole DE; Taylor GA; Cutrara M; Samuels TH; Murphy JP; Murphy JM; Narod SA
J Clin Oncol; 2001 Aug; 19(15):3524-31. PubMed ID: 11481359
[TBL] [Abstract][Full Text] [Related]
60. Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic.
Laitman Y; Feldman DM; Sklair-Levy M; Yosepovich A; Barshack-Nakar I; Brodsky M; Halshtok O; Shalmon A; Gotlieb M; Friedman E
Clin Breast Cancer; 2018 Aug; 18(4):e695-e698. PubMed ID: 29292184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
